Terbinafine in fungal infections of the nails: a meta-analysis of randomized clinical trials

被引:28
作者
Haugh, M
Helou, S
Boissel, JP
Cribier, BJ
机构
[1] Hop Univ, Dermatol Clin, F-67091 Strasbourg, France
[2] Ctr Leon Berard, Ctr Cochrane Francais, F-69373 Lyon 08, France
关键词
griseofulvin; itraconazole; meta-analysis; onychomycosis; terbinafine;
D O I
10.1046/j.1365-2133.2002.04825.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Historically, there has been a general resistance to treating onychomycosis on the basis that such treatments were protracted and of uncertain outcome. However, modern treatments act more promptly and reliably. Objectives To carry out a meta-analysis to evaluate the efficacy and safety of terbinafine in comparison with placebo, itraconazole and griseofulvin. Methods The analysis used data from published trials, supplemented where necessary by reference to the original trial reports. Results Three trials were included in which terbinafine was compared with placebo. From four trials comparing terbinafine with itraconazole, a statistically significant advantage in favour of terbinafine was observed for negative culture and microscopy at the end of the trials. Furthermore, both patients and physicians reported terbinafine to be better tolerated than itraconazole. From two trials comparing terbinafine with griseofulvin, a significantly higher rate of negative microscopy and culture was observed with terbinafine. Conclusions A significant advantage in favour of treatment with terbinafine was observed.
引用
收藏
页码:118 / 121
页数:4
相关论文
共 13 条
  • [1] Brautigam M, 1995, BMJ-BRIT MED J, V311, P191
  • [2] EasyMA: A program for the meta-analysis of clinical trials
    Cucherat, M
    Boissel, JP
    Leizorovicz, A
    Haugh, MC
    [J]. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 1997, 53 (03) : 187 - 190
  • [3] Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial
    Drake, LA
    Shear, NH
    Arlette, JP
    Cloutier, R
    Danby, FW
    Elewski, BE
    GarnisJones, S
    Giroux, JM
    Gratton, D
    Gulliver, W
    Hull, P
    Jones, HE
    Journet, M
    Krol, AL
    Leyden, JJ
    Maddin, SC
    Ross, JB
    Savin, RC
    Scher, RK
    Sibbald, GR
    Tawfik, NH
    Zaias, N
    Tolpin, M
    Evans, S
    Marsolais, C
    Chin, T
    Lin, TH
    Maher, T
    Birnbaum, JE
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 37 (05) : 740 - 745
  • [4] Risk factors for erysipelas of the leg (cellulitis): case-control study
    Dupuy, A
    Benchikhi, H
    Roujeau, JC
    Bernard, P
    Vaillant, L
    Chosidov, O
    Sassolas, B
    Guillaume, JC
    Grob, JJ
    Bastuji-Garin, S
    [J]. BRITISH MEDICAL JOURNAL, 1999, 318 (7198) : 1591 - 1594
  • [5] Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis
    Evans, EGV
    Sigurgeirsson, B
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1999, 318 (7190): : 1031 - 1035
  • [6] SHORT-TERM TREATMENT OF DERMATOPHYTE ONYCHOMYCOSIS WITH TERBINAFINE
    GOODFIELD, MJD
    ANDREW, L
    EVANS, EGV
    [J]. BRITISH MEDICAL JOURNAL, 1992, 304 (6835) : 1151 - 1154
  • [7] SHORT-DURATION TREATMENT OF FINGERNAIL DERMATOPHYTOSIS - A RANDOMIZED, DOUBLE-BLIND-STUDY WITH TERBINAFINE AND GRISEOFULVIN
    HANEKE, E
    TAUSCH, I
    BRAUTIGAM, M
    WEIDINGER, G
    WELZEL, D
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1995, 32 (01) : 72 - 77
  • [8] TREATMENT OF TOENAIL ONYCHOMYCOSIS - A RANDOMIZED, DOUBLE-BLIND-STUDY WITH TERBINAFINE AND GRISEOFULVIN
    HOFMANN, H
    BRAUTIGAM, M
    WEIDINGER, G
    ZAUN, H
    ALTMEYER, P
    ANTAL, I
    BERNS, W
    BORELLI, S
    DIETERLE, R
    FRIEDERICH, HC
    GLOWANIA, HJ
    GOOS, M
    HANEKE, E
    HOLZMANN, H
    JUNG, EG
    KNOP, J
    KREYSEL, HW
    MARGHESCU, S
    MENSING, H
    PAUL, E
    PETRES, J
    REINEL, D
    ROSINUS, A
    SCHOPF, R
    TRONNIER, H
    [J]. ARCHIVES OF DERMATOLOGY, 1995, 131 (08) : 919 - 922
  • [9] Itraconazole versus terbinafine (LAMISIL®):: which is better for the treatment of onychomycosis?
    Honeyman, JF
    Talarico, S
    Arruda, LHF
    Pereira, AC
    Santamaria, JR
    Souza, EM
    Woscoff, A
    Amorim, R
    De la Parra, CR
    Enokihara, MY
    Gavazoni, MF
    Gubelin, HW
    Rosa, SP
    Turini, MAG
    Vitale, MA
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 1997, 9 (03) : 215 - 221
  • [10] Epidemiology of onychomycosis in special-risk populations
    Levy, LA
    [J]. JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION, 1997, 87 (12): : 546 - 550